Debra M. Prow

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Thomas Powles, Piotr Tomczak, Se Hoon Park et al. · The Lancet Oncology · 2022 · 262 citations · Full text

Randomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus Placebo for Aromatase Inhibitor–Associated Arthralgias in Early-Stage Breast Cancer: SWOG S1202

N. Lynn Henry, Joseph M. Unger, Anne F. Schott et al. · Journal of Clinical Oncology · 2017 · 112 citations · Full text

Pain Therapy, Pain Disorders, Breast Oncology +22

A dose-finding and safety study of novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia in patients receiving multicycle chemotherapy

John A. Glaspy, J. Jadeja, Glen R. Justice et al. · British Journal of Cancer · 2001 · 81 citations · Full text

Gene expression profiling identifies responsive patients with cancer of unknown primary treated with carboplatin, paclitaxel, and everolimus: NCCTG N0871 (alliance)

Han‐Seung Yoon, Nathan R. Foster, J. Meyers et al. · Annals of Oncology · 2015 · 57 citations · Full text

Ncctg N0871, Oncology, Medicine +9

Alternating dose-dense chemotherapy in patients with high volume disseminated non-seminomatous germ cell tumours

Karim Fizazi, Debra M. Prow, K-A. Do et al. · British Journal of Cancer · 2002 · 34 citations · Full text